25 XP   0   0   10

Acasti Pharma Inc
Buy, Hold or Sell?

Let's analyse Acasti Pharma Inc together

PenkeI guess you are interested in Acasti Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Acasti Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Acasti Pharma Inc

I send you an email if I find something interesting about Acasti Pharma Inc.

Quick analysis of Acasti Pharma Inc (30 sec.)










What can you expect buying and holding a share of Acasti Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.29
Expected worth in 1 year
$-7.26
How sure are you?
45.5%

+ What do you gain per year?

Total Gains per Share
$-12.55
Return On Investment
-432.8%

For what price can you sell your share?

Current Price per Share
$2.90
Expected price per share
$1.98 - $3.325
How sure are you?
50%

1. Valuation of Acasti Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$2.90

Intrinsic Value Per Share

$-14.35 - $-0.54

Total Value Per Share

$-9.06 - $4.75

2. Growth of Acasti Pharma Inc (5 min.)




Is Acasti Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$49.7m$79.2m-$29.4m-59.3%

How much money is Acasti Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$31m-$7.1m-$23.8m-76.9%
Net Profit Margin0.0%-75,530.8%--

How much money comes from the company's main activities?

3. Financial Health of Acasti Pharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#481 / 1010

Most Revenue
#1004 / 1010

Most Profit
#493 / 1010

What can you expect buying and holding a share of Acasti Pharma Inc? (5 min.)

Welcome investor! Acasti Pharma Inc's management wants to use your money to grow the business. In return you get a share of Acasti Pharma Inc.

What can you expect buying and holding a share of Acasti Pharma Inc?

First you should know what it really means to hold a share of Acasti Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Acasti Pharma Inc is $2.9. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acasti Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acasti Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.29. Based on the TTM, the Book Value Change Per Share is $-3.14 per quarter. Based on the YOY, the Book Value Change Per Share is $4.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acasti Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.30-113.9%-3.30-113.9%-0.76-26.4%-2.13-73.4%-1.36-47.0%
Usd Book Value Change Per Share-3.14-108.2%-3.14-108.2%4.09141.2%0.9633.1%0.4114.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-3.14-108.2%-3.14-108.2%4.09141.2%0.9633.1%0.4114.3%
Usd Price Per Share0.46-0.46-1.22-0.74-0.95-
Price to Earnings Ratio-0.14--0.14--1.60--0.53--1.81-
Price-to-Total Gains Ratio-0.15--0.15-0.30-1.09--2.36-
Price to Book Ratio0.09-0.09-0.14-0.40-0.71-
Price-to-Total Gains Ratio-0.15--0.15-0.30-1.09--2.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.9
Number of shares344
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-3.140.96
Usd Total Gains Per Share-3.140.96
Gains per Quarter (344 shares)-1,079.44329.80
Gains per Year (344 shares)-4,317.761,319.20
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4318-4328013191309
20-8636-8646026382628
30-12953-12964039583947
40-17271-17282052775266
50-21589-21600065966585
60-25907-25918079157904
70-30224-30236092349223
80-34542-3455401055410542
90-38860-3887201187311861
100-43178-4319001319213180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.011.00.00.0%0.015.00.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.06.00.045.5%7.08.00.046.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.011.00.0%0.00.015.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.06.00.045.5%7.08.00.046.7%

Fundamentals of Acasti Pharma Inc

About Acasti Pharma Inc

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Fundamental data was last updated by Penke on 2024-04-10 23:32:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Acasti Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Acasti Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acasti Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-75,530.8%+75,530.8%
TTM-5Y-17,114.1%+17,114.1%
5Y-17,114.1%10Y-9,570.5%-7,543.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--218.5%+218.5%
YOY-75,530.8%-284.8%-75,246.0%
5Y-17,114.1%-435.1%-16,679.0%
10Y-9,570.5%-589.3%-8,981.2%
1.1.2. Return on Assets

Shows how efficient Acasti Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • -53.6% Return on Assets means that Acasti Pharma Inc generated $-0.54 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acasti Pharma Inc:

  • The MRQ is -53.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -53.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-53.6%TTM-53.6%0.0%
TTM-53.6%YOY-7.6%-46.0%
TTM-53.6%5Y-65.3%+11.6%
5Y-65.3%10Y-50.7%-14.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-53.6%-13.2%-40.4%
TTM-53.6%-12.7%-40.9%
YOY-7.6%-11.5%+3.9%
5Y-65.3%-13.8%-51.5%
10Y-50.7%-15.5%-35.2%
1.1.3. Return on Equity

Shows how efficient Acasti Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • -62.4% Return on Equity means Acasti Pharma Inc generated $-0.62 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acasti Pharma Inc:

  • The MRQ is -62.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -62.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-62.4%TTM-62.4%0.0%
TTM-62.4%YOY-9.1%-53.4%
TTM-62.4%5Y-144.9%+82.5%
5Y-144.9%10Y-104.8%-40.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62.4%-16.8%-45.6%
TTM-62.4%-16.0%-46.4%
YOY-9.1%-14.8%+5.7%
5Y-144.9%-19.3%-125.6%
10Y-104.8%-20.0%-84.8%

1.2. Operating Efficiency of Acasti Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Acasti Pharma Inc is operating .

  • Measures how much profit Acasti Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acasti Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-119,915.4%+119,915.4%
TTM-5Y-25,076.5%+25,076.5%
5Y-25,076.5%10Y-14,330.2%-10,746.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.8%+299.8%
TTM--239.2%+239.2%
YOY-119,915.4%-295.4%-119,620.0%
5Y-25,076.5%-485.9%-24,590.6%
10Y-14,330.2%-624.6%-13,705.6%
1.2.2. Operating Ratio

Measures how efficient Acasti Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2,379.154-2,379.154
TTM-5Y486.965-486.965
5Y486.96510Y250.948+236.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.238-3.238
TTM-3.313-3.313
YOY2,379.1543.838+2,375.316
5Y486.9655.675+481.290
10Y250.9487.612+243.336

1.3. Liquidity of Acasti Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Acasti Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.59 means the company has $8.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acasti Pharma Inc:

  • The MRQ is 8.587. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.587. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.587TTM8.5870.000
TTM8.587YOY13.967-5.380
TTM8.5875Y13.255-4.668
5Y13.25510Y11.011+2.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5873.870+4.717
TTM8.5874.173+4.414
YOY13.9675.332+8.635
5Y13.2556.126+7.129
10Y11.0116.448+4.563
1.3.2. Quick Ratio

Measures if Acasti Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 8.42 means the company can pay off $8.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acasti Pharma Inc:

  • The MRQ is 8.416. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.416. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.416TTM8.4160.000
TTM8.416YOY17.648-9.232
TTM8.4165Y15.136-6.720
5Y15.13610Y14.536+0.601
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4163.510+4.906
TTM8.4163.994+4.422
YOY17.6485.357+12.291
5Y15.1366.105+9.031
10Y14.5366.404+8.132

1.4. Solvency of Acasti Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Acasti Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acasti Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that Acasti Pharma Inc assets are financed with 14.1% credit (debt) and the remaining percentage (100% - 14.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.141. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.141. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.1410.000
TTM0.141YOY0.158-0.017
TTM0.1415Y0.310-0.169
5Y0.31010Y0.265+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.339-0.198
TTM0.1410.336-0.195
YOY0.1580.271-0.113
5Y0.3100.368-0.058
10Y0.2650.388-0.123
1.4.2. Debt to Equity Ratio

Measures if Acasti Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 16.4% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.164. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.164. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.164TTM0.1640.000
TTM0.164YOY0.188-0.024
TTM0.1645Y0.741-0.577
5Y0.74110Y0.581+0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1640.390-0.226
TTM0.1640.402-0.238
YOY0.1880.339-0.151
5Y0.7410.428+0.313
10Y0.5810.461+0.120

2. Market Valuation of Acasti Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acasti Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A PE ratio of -0.14 means the investor is paying $-0.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acasti Pharma Inc:

  • The EOD is -0.878. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.139. Based on the earnings, the company is expensive. -2
  • The TTM is -0.139. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.878MRQ-0.139-0.739
MRQ-0.139TTM-0.1390.000
TTM-0.139YOY-1.596+1.457
TTM-0.1395Y-0.530+0.391
5Y-0.53010Y-1.808+1.278
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.878-2.296+1.418
MRQ-0.139-2.600+2.461
TTM-0.139-2.726+2.587
YOY-1.596-4.145+2.549
5Y-0.530-6.259+5.729
10Y-1.808-6.348+4.540
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acasti Pharma Inc:

  • The EOD is -2.339. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.371. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.371. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.339MRQ-0.371-1.968
MRQ-0.371TTM-0.3710.000
TTM-0.371YOY-0.909+0.539
TTM-0.3715Y-0.511+0.140
5Y-0.51110Y-1.008+0.498
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.339-2.937+0.598
MRQ-0.371-3.326+2.955
TTM-0.371-3.553+3.182
YOY-0.909-5.605+4.696
5Y-0.511-8.385+7.874
10Y-1.008-8.882+7.874
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Acasti Pharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.09 means the investor is paying $0.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acasti Pharma Inc:

  • The EOD is 0.548. Based on the equity, the company is cheap. +2
  • The MRQ is 0.087. Based on the equity, the company is cheap. +2
  • The TTM is 0.087. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.548MRQ0.087+0.461
MRQ0.087TTM0.0870.000
TTM0.087YOY0.145-0.058
TTM0.0875Y0.400-0.313
5Y0.40010Y0.708-0.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5481.909-1.361
MRQ0.0872.114-2.027
TTM0.0872.096-2.009
YOY0.1452.884-2.739
5Y0.4003.554-3.154
10Y0.7083.938-3.230
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acasti Pharma Inc.

3.1. Institutions holding Acasti Pharma Inc

Institutions are holding 6.09% of the shares of Acasti Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Bank of America Corp5.26310.000149469800
2023-12-31ADAR1 Capital Management LLC0.36740.035734532345320
2023-12-31Royal Bank of Canada0.336031584310005308.2192
2023-12-31UBS Group AG0.05960560289018.8879
2023-12-31Morgan Stanley - Brokerage Accounts0.020188200
2023-12-31Advisory Services Network, LLC0.0004041410
2023-12-31ICA Group Wealth Management, LLC0.00010990
2023-09-30Nbc Securities Inc00220
2023-12-31TD Waterhouse Canada Inc000-1-100
2023-12-31JPMorgan Chase & Co000-3358-100
2023-12-31LLBH Private Wealth Management, LLC000-10000-100
2023-09-30TWO SIGMA SECURITIES, LLC000-2514-100
Total 6.04660.0358568350+50601+8.9%

3.2. Funds holding Acasti Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.03250.0001305800
2024-03-28Unusual Whales Subversive Rep Trd ETF0.0160.0381150000
Total 0.04850.0382455800.0%

3.3. Insider Transactions

Insiders are holding 16.021% of the shares of Acasti Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-25Vimal KavuruBUY6763711.85
2023-08-31Donald OldsBUY3812.05

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Acasti Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.138-3.1380%4.095-177%0.959-427%0.414-859%
Book Value Per Share--5.2895.2890%8.427-37%3.975+33%2.627+101%
Current Ratio--8.5878.5870%13.967-39%13.255-35%11.011-22%
Debt To Asset Ratio--0.1410.1410%0.158-11%0.310-55%0.265-47%
Debt To Equity Ratio--0.1640.1640%0.188-13%0.741-78%0.581-72%
Dividend Per Share----0%-0%-0%-0%
Eps---3.302-3.3020%-0.764-77%-2.130-36%-1.363-59%
Free Cash Flow Per Share---1.240-1.2400%-1.341+8%-1.489+20%-1.063-14%
Free Cash Flow To Equity Per Share---1.216-1.2160%1.358-190%0.873-239%0.520-334%
Gross Profit Margin--1.0031.0030%1.053-5%1.043-4%1.020-2%
Intrinsic Value_10Y_max---0.536--------
Intrinsic Value_10Y_min---14.346--------
Intrinsic Value_1Y_max---0.847--------
Intrinsic Value_1Y_min---1.491--------
Intrinsic Value_3Y_max---1.941--------
Intrinsic Value_3Y_min---4.461--------
Intrinsic Value_5Y_max---2.305--------
Intrinsic Value_5Y_min---7.385--------
Market Cap27258260.000+84%4322784.0604322784.0600%11467268.000-62%6916830.472-38%8936436.825-52%
Net Profit Margin----0%-755.3080%-171.1410%-95.7050%
Operating Margin----0%-1199.1540%-250.7650%-143.3020%
Operating Ratio----0%2379.154-100%486.965-100%250.948-100%
Pb Ratio0.548+84%0.0870.0870%0.145-40%0.400-78%0.708-88%
Pe Ratio-0.878-531%-0.139-0.1390%-1.596+1046%-0.530+281%-1.808+1198%
Price Per Share2.900+84%0.4600.4600%1.220-62%0.736-38%0.951-52%
Price To Free Cash Flow Ratio-2.339-531%-0.371-0.3710%-0.909+145%-0.511+38%-1.008+172%
Price To Total Gains Ratio-0.924-531%-0.147-0.1470%0.298-149%1.092-113%-2.357+1508%
Quick Ratio--8.4168.4160%17.648-52%15.136-44%14.536-42%
Return On Assets---0.536-0.5360%-0.076-86%-0.653+22%-0.507-5%
Return On Equity---0.624-0.6240%-0.091-85%-1.449+132%-1.048+68%
Total Gains Per Share---3.138-3.1380%4.095-177%0.959-427%0.414-859%
Usd Book Value--49715878.00049715878.0000%79210332.000-37%37360743.035+33%24689843.696+101%
Usd Book Value Change Per Share---3.138-3.1380%4.095-177%0.959-427%0.414-859%
Usd Book Value Per Share--5.2895.2890%8.427-37%3.975+33%2.627+101%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---3.302-3.3020%-0.764-77%-2.130-36%-1.363-59%
Usd Free Cash Flow---11654388.000-11654388.0000%-12608394.400+8%-13997295.138+20%-8174105.221-30%
Usd Free Cash Flow Per Share---1.240-1.2400%-1.341+8%-1.489+20%-1.063-14%
Usd Free Cash Flow To Equity Per Share---1.216-1.2160%1.358-190%0.873-239%0.520-334%
Usd Market Cap27258260.000+84%4322784.0604322784.0600%11467268.000-62%6916830.472-38%8936436.825-52%
Usd Price Per Share2.900+84%0.4600.4600%1.220-62%0.736-38%0.951-52%
Usd Profit---31041056.400-31041056.4000%-7183580.400-77%-20711243.920-33%-12712956.845-59%
Usd Revenue----0%9510.800-100%30580.880-100%60073.517-100%
Usd Total Gains Per Share---3.138-3.1380%4.095-177%0.959-427%0.414-859%
 EOD+5 -3MRQTTM+0 -0YOY+8 -245Y+13 -1910Y+10 -22

4.2. Fundamental Score

Let's check the fundamental score of Acasti Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.878
Price to Book Ratio (EOD)Between0-10.548
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.416
Current Ratio (MRQ)Greater than18.587
Debt to Asset Ratio (MRQ)Less than10.141
Debt to Equity Ratio (MRQ)Less than10.164
Return on Equity (MRQ)Greater than0.15-0.624
Return on Assets (MRQ)Greater than0.05-0.536
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Acasti Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.029
Ma 20Greater thanMa 503.218
Ma 50Greater thanMa 1003.308
Ma 100Greater thanMa 2002.884
OpenGreater thanClose2.798
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
EBIT  -24,6656,786-17,87910,039-7,840-3,565-11,40522,90811,503
EBITDA  -22,6716,702-15,9698,691-7,279-7,345-14,62426,21811,594
Operating Income  -24,6656,786-17,87910,039-7,840-3,565-11,40522,90811,503



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets79,123
Total Liabilities11,168
Total Stockholder Equity67,955
 As reported
Total Liabilities 11,168
Total Stockholder Equity+ 67,955
Total Assets = 79,123

Assets

Total Assets79,123
Total Current Assets29,290
Long-term Assets49,833
Total Current Assets
Cash And Cash Equivalents 27,875
Short-term Investments 15
Net Receivables 802
Other Current Assets 598
Total Current Assets  (as reported)29,290
Total Current Assets  (calculated)29,290
+/-0
Long-term Assets
Property Plant Equipment 567
Goodwill 8,138
Intangible Assets 41,128
Long-term Assets  (as reported)49,833
Long-term Assets  (calculated)49,833
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,411
Long-term Liabilities7,757
Total Stockholder Equity67,955
Total Current Liabilities
Short-term Debt 75
Accounts payable 1,242
Other Current Liabilities 3,336
Total Current Liabilities  (as reported)3,411
Total Current Liabilities  (calculated)4,653
+/- 1,242
Long-term Liabilities
Capital Lease Obligations 485
Long-term Liabilities  (as reported)7,757
Long-term Liabilities  (calculated)485
+/- 7,272
Total Stockholder Equity
Common Stock258,294
Retained Earnings -198,266
Accumulated Other Comprehensive Income -6,038
Other Stockholders Equity 13,965
Total Stockholder Equity (as reported)67,955
Total Stockholder Equity (calculated)67,955
+/-0
Other
Capital Stock258,294
Cash and Short Term Investments 27,890
Common Stock Shares Outstanding 7,435
Current Deferred Revenue-1,242
Liabilities and Stockholders Equity 79,123
Net Debt -27,390
Net Invested Capital 67,955
Net Working Capital 25,879
Property Plant and Equipment Gross 1,176
Short Long Term Debt Total 485



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312017-02-282016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-31
> Total Assets 
889
3,403
15,820
11,888
41,011
29,739
21,044
19,908
18,842
17,778
36,302
22,853
62,458
128,620
79,123
79,123128,62062,45822,85336,30217,77818,84219,90821,04429,73941,01111,88815,8203,403889
   > Total Current Assets 
860
3,365
8,908
5,724
23,203
15,699
8,358
8,241
10,281
7,350
27,959
16,079
62,372
45,531
29,290
29,29045,53162,37216,07927,9597,35010,2818,2418,35815,69923,2035,7248,9083,365860
       Cash And Cash Equivalents 
393
329
1,599
1,169
607
1,047
2,234
7,983
7,233
6,367
16,867
14,240
50,942
30,339
27,875
27,87530,33950,94214,24016,8676,3677,2337,9832,2341,0476071,1691,599329393
       Short-term Investments 
0
2,564
5,575
3,505
20,695
13,644
5,493
0
0
0
8,886
5
9,789
13,322
15
1513,3229,78958,8860005,49313,64420,6953,5055,5752,5640
       Net Receivables 
468
456
1,089
817
1,034
683
294
125
206
588
1,188
546
530
548
802
8025485305461,1885882061252946831,0348171,089456468
       Other Current Assets 
0
15
42
16
632
255
337
133
0
81
49
195
1,111
1,322
598
5981,3221,111195498101333372556321642150
   > Long-term Assets 
28
39
6,912
6,164
17,809
14,040
12,687
0
0
10,428
8,343
6,774
86
83,089
49,833
49,83383,089866,7748,34310,4280012,68714,04017,8096,1646,9123928
       Property Plant Equipment 
28
39
27
19
35
56
212
2,167
2,787
2,184
2,107
2,057
86
315
567
567315862,0572,1072,1842,7872,167212563519273928
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
12,964
8,138
8,13812,9640000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
20
20
0
0
0
0
00002020000000000
       Intangible Assets 
0
0
6,885
6,145
17,774
13,984
10,999
9,500
9,170
7,794
5,799
4,244
0
69,810
41,128
41,12869,81004,2445,7997,7949,1709,50010,99913,98417,7746,1456,88500
       Other Assets 
0
0
0
0
23
0
0
0
0
0
0
0
0
0
0
0000000000230000
> Total Liabilities 
4,533
5,241
1,267
2,390
11,102
3,181
957
3,006
2,778
11,410
25,846
9,859
6,798
20,350
11,168
11,16820,3506,7989,85925,84611,4102,7783,0069573,18111,1022,3901,2675,2414,533
   > Total Current Liabilities 
4,533
967
1,267
2,390
1,052
1,297
842
1,816
2,138
5,186
13,665
7,395
1,579
3,260
3,411
3,4113,2601,5797,39513,6655,1862,1381,8168421,2971,0522,3901,2679674,533
       Short-term Debt 
0
0
0
0
0
1
0
11
0
0
1,361
76
86
104
75
7510486761,36100110100000
       Short Long Term Debt 
0
0
0
0
0
1
0
11
0
0
1,361
0
0
0
0
00001,36100110100000
       Accounts payable 
0
974
552
318
287
197
277
1,805
259
2,648
3,044
1,713
115
1,678
1,242
1,2421,6781151,7133,0442,6482591,8052771972873185529740
       Other Current Liabilities 
4,533
967
714
2,072
765
1,100
565
0
0
2,538
9,261
5,606
1,378
1,478
3,336
3,3361,4781,3785,6069,2612,538005651,1007652,0727149674,533
   > Long-term Liabilities 
0
4,274
552
318
10,049
1,884
115
0
0
6,224
12,180
2,464
5,219
17,090
7,757
7,75717,0905,2192,46412,1806,224001151,88410,0493185524,2740
       Long term Debt Total 
0
0
0
0
0
0
0
0
1,041
1,193
0
0
0
0
0
000001,1931,04100000000
       Other Liabilities 
0
132
0
0
10,104
1,881
156
0
209
6,426
12,183
2,393
5,219
16,899
0
016,8995,2192,39312,1836,42620901561,88110,104001320
> Total Stockholder Equity
-3,644
-1,838
14,553
9,498
29,910
26,558
20,087
16,902
16,064
6,368
10,457
12,994
55,660
108,270
67,955
67,955108,27055,66012,99410,4576,36816,06416,90220,08726,55829,9109,49814,553-1,838-3,644
   Common Stock
7,362
12,310
28,916
28,252
54,848
49,256
45,733
50,267
66,576
56,789
96,853
137,424
197,194
257,990
258,294
258,294257,990197,194137,42496,85356,78966,57650,26745,73349,25654,84828,25228,91612,3107,362
   Retained Earnings -198,266-155,837-146,018-126,340-92,829-56,046-50,875-37,832-29,243-26,624-28,451-19,579-13,228-14,256-11,006
   Capital Surplus 
0
0
0
0
0
0
0
0
4,214
5,149
8,150
9,797
0
0
0
0009,7978,1505,1494,21400000000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
133
27,817
868
3,556
3,967
3,679
233
309
6,153
7,321
9,797
10,817
12,154
13,965
13,96512,15410,8179,7977,3216,1533092333,6793,9673,55686827,8171330



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-52,155
Gross Profit-52,155-52,155
 
Operating Income (+$)
Gross Profit-52,155
Operating Expense-18,247
Operating Income15,723-70,402
 
Operating Expense (+$)
Research Development9,972
Selling General Administrative8,076
Selling And Marketing Expenses136
Operating Expense18,24718,184
 
Net Interest Income (+$)
Interest Income246
Interest Expense-67,694
Other Finance Cost-67,694
Net Interest Income246
 
Pretax Income (+$)
Operating Income15,723
Net Interest Income246
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-51,97183,417
EBIT - interestExpense = -51,971
-51,971
25,265
Interest Expense67,694
Earnings Before Interest and Taxes (EBIT)15,72315,723
Earnings Before Interest and Taxes (EBITDA)15,847
 
After tax Income (+$)
Income Before Tax-51,971
Tax Provision--9,542
Net Income From Continuing Ops-42,429-42,429
Net Income-42,429
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses18,247
Total Other Income/Expenses Net-67,694-246
 

Technical Analysis of Acasti Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acasti Pharma Inc. The general trend of Acasti Pharma Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acasti Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acasti Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.2629 < 3.2939 < 3.325.

The bearish price targets are: 2.25 > 2 > 1.98.

Tweet this
Acasti Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acasti Pharma Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acasti Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acasti Pharma Inc. The current macd is -0.11586662.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acasti Pharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Acasti Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Acasti Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acasti Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAcasti Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acasti Pharma Inc. The current adx is 26.38.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Acasti Pharma Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Acasti Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acasti Pharma Inc. The current sar is 3.16.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Acasti Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acasti Pharma Inc. The current rsi is 26.03. The current phase is Oversold in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bull market: Short-term excessive selling, potential for rebound. Consider buying at a perceived discount, watch for reversal signs. +1
  • Trending down: The RSI is trending down. -1
Acasti Pharma Inc Daily Relative Strength Index (RSI) ChartAcasti Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acasti Pharma Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acasti Pharma Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Acasti Pharma Inc Daily Stochastic Oscillator ChartAcasti Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acasti Pharma Inc. The current cci is -98.17367432.

Acasti Pharma Inc Daily Commodity Channel Index (CCI) ChartAcasti Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acasti Pharma Inc. The current cmo is -58.89474977.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Acasti Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAcasti Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acasti Pharma Inc. The current willr is -79.85734222.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Acasti Pharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Acasti Pharma Inc Daily Williams %R ChartAcasti Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acasti Pharma Inc.

Acasti Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acasti Pharma Inc. The current atr is 0.13850502.

Acasti Pharma Inc Daily Average True Range (ATR) ChartAcasti Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acasti Pharma Inc. The current obv is 2,215,195.

Acasti Pharma Inc Daily On-Balance Volume (OBV) ChartAcasti Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acasti Pharma Inc. The current mfi is 28.26.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acasti Pharma Inc Daily Money Flow Index (MFI) ChartAcasti Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acasti Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Acasti Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acasti Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.029
Ma 20Greater thanMa 503.218
Ma 50Greater thanMa 1003.308
Ma 100Greater thanMa 2002.884
OpenGreater thanClose2.798
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Acasti Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Acasti Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acasti Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acasti Pharma Inc

I send you an email if I find something interesting about Acasti Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Acasti Pharma Inc.

Receive notifications about Acasti Pharma Inc in your mailbox!